Home » Reports » AOLS to initiate clinical research for testing the efficacy of AEOL 10150 Aeolus Pharmaceuticals.

AOLS to initiate clinical research for testing the efficacy of AEOL 10150 Aeolus Pharmaceuticals.

The program is made to augment and accelerate the advancement of implantable digital sensors and the advancement and application of virtual prototyping simulation models, that may ultimately help the amputee better control the prosthetic. This critically important system is expected to create a model for developing a unique, than a one-size suits all rather, robotic prosthetic gadget for an amputee, lower costs for embedding sensors within a limb, and a sophisticated integrated control system that allows for lighter, more comfortable and more cost-effective prostheses, stated Back Admiral Richard Brooks, USN , Alion’s Distributed Simulation Group Supervisor.The fourth one fourth and full year 2010 included non-cash impairment charges totaling $42.1 million, or $25.7 million net of tax. Alliance believes that the reduction in fair value which prompted the impairment costs is because sustained high unemployment rates, a reported decline in physician office visits, and additional conditions in the usa arising from global fiscal conditions. These factors have had a sustained negative impact on the Company’s stock cost and on the reasonable worth of its reporting products. As a result, Alliance recorded non-cash impairment fees in the fourth quarter and full year 2010.